Biologics

Mark Miller, MD, is an orthopedic sports medicine surgeon and orthopedic surgery professor at the University of Virginia in Charlottesville.

Sirakoss received CE mark approval for its Osteo3, a new nano-synthetic bone graft substitute designed for use in bone fracture repair.

Seth L. Sherman, MD, enrolled and operated on four patients in a study of CartiHeal's Agili-C knee cartilage repair implant.  

Orthobiologics company Biogennix named Robert Bazier its new CFO.

Regenerative medicine company CollPlant appointed Jonathan M.N. Rigby as chairman of the board of directors.

Ortho Regenerative Technologies published the results of two scientific studies validating its product's ability to improve the repair of rotator cuff tendon and articular cartilage tissue.

The Pacific Brain Tumor Center at Santa Monica, Calif.-based Pacific Neuroscience Institute will serve as the leading enrollment site for Medicenna Therapeutics' clinical trial.

ThermoGenesis Corp. entered into a supply agreement with Los Angeles-based Orthohealing Center Management.

The CDC is investigating bacterial infections in patients who received stem cell treatments from the ReGen Series, distributed by Liveyon.

The global spine biologics market is expected to reach $2.7 billion by 2024, increasing at a 4.4 percent compound annual growth rate, according to a Data Bridge Market Research report.